Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors

Overview

Journal Surg Oncol Clin N Am

Specialties General Surgery
Oncology

Date 2020 Mar 11

PMID 32151355

Citations 7

Authors

Andrew M Bellizzi

Affiliations

Soon will be listed here.

Abstract

This review serves as a primer on contemporary neuroendocrine neoplasm classification, with an emphasis on gastroenteropancreatic well-differentiated neuroendocrine tumors. Topics discussed include general features of neuroendocrine neoplasms, general neuroendocrine marker immunohistochemistry, the distinction of well-differentiated neuroendocrine tumor from pheochromocytoma/paraganglioma and other diagnostic mimics and poorly differentiated neuroendocrine carcinoma from diagnostic mimics, the concepts of differentiation and grade and the application of Ki-67 immunohistochemistry to determine the latter, the various WHO classifications of neuroendocrine neoplasms including the 2019 WHO classification of gastroenteropancreatic tumors, organ-specific considerations for gastroenteropancreatic well-differentiated neuroendocrine tumors, immunohistochemistry to determine site of origin in metastatic well-differentiated neuroendocrine tumor of occult origin, immunohistochemistry in the distinction of well-differentiated neuroendocrine tumor G3 from large cell neuroendocrine carcinoma, and, finally, required and recommended reporting elements for biopsies and resections of gastroenteropancreatic neuroendocrine epithelial neoplasms.

Citing Articles

Clinicopathologic characteristics of neuroendocrine tumors with assessment by digital image analysis for Ki-67 index with a focus on the gastroenteropancreatic tract: a single-center study.

Park J, Shin S, Jeon N, Lim B Int J Clin Exp Pathol. 2023; 16(9):225-234.

PMID: 37818384 PMC: 10560883.

Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms.

Bourdeleau P, Couvelard A, Ronot M, Lebtahi R, Hentic O, Ruszniewski P Ther Adv Med Oncol. 2023; 15:17588359231179310.

PMID: 37323185 PMC: 10262621. DOI: 10.1177/17588359231179310.

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).

Castillon J, Alonso Gordoa T, Bayonas A, Carretero A, Garcia-Carbonero R, Pulido E Clin Transl Oncol. 2023; 25(9):2692-2706.

PMID: 37204633 PMC: 10425298. DOI: 10.1007/s12094-023-03205-6.

Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging.

Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T Cancers (Basel). 2022; 14(10).

PMID: 35626118 PMC: 9139608. DOI: 10.3390/cancers14102514.

An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs.

Couvelard A, Cros J Virchows Arch. 2022; 480(6):1129-1148.

PMID: 35278097 DOI: 10.1007/s00428-022-03306-7.

References

Busam K, Jungbluth A, Rekthman N, Coit D, Pulitzer M, Bini J . Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas. Am J Surg Pathol. 2009; 33(9):1378-85. PMC: 2932664. DOI: 10.1097/PAS.0b013e3181aa30a5. View

Bellizzi A . SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology. 2019; 76(2):251-264. PMC: 6917843. DOI: 10.1111/his.13943. View

Tang L, Gonen M, Hedvat C, Modlin I, Klimstra D . Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012; 36(12):1761-70. DOI: 10.1097/PAS.0b013e318263207c. View

Pelosi G, Rodriguez J, Viale G, Rosai J . Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005; 29(2):179-87. DOI: 10.1097/01.pas.0000149690.75462.29. View

Perrino C, Ho A, Dall C, Zynger D . Utility of GATA3 in the differential diagnosis of pheochromocytoma. Histopathology. 2017; 71(3):475-479. DOI: 10.1111/his.13229. View

Tang L, Untch B, Reidy D, OReilly E, Dhall D, Jih L . Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2015; 22(4):1011-7. PMC: 4988130. DOI: 10.1158/1078-0432.CCR-15-0548. View

Rekhtman N, Pietanza M, Hellmann M, Naidoo J, Arora A, Won H . Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clin Cancer Res. 2016; 22(14):3618-29. PMC: 4995776. DOI: 10.1158/1078-0432.CCR-15-2946. View

Grillo F, Albertelli M, Brisigotti M, Borra T, Boschetti M, Fiocca R . Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor. Neuroendocrinology. 2015; 103(5):452-9. DOI: 10.1159/000439434. View

Yachida S, Vakiani E, White C, Zhong Y, Saunders T, Morgan R . Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012; 36(2):173-84. PMC: 3261427. DOI: 10.1097/PAS.0b013e3182417d36. View

10.

Basturk O, Yang Z, Tang L, Hruban R, Adsay V, McCall C . The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015; 39(5):683-90. PMC: 4398606. DOI: 10.1097/PAS.0000000000000408. View

11.

Zen Y, Heaton N . Elevated Ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor. Pathol Int. 2013; 63(11):532-8. DOI: 10.1111/pin.12108. View

12.

Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P . Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017; 543(7643):65-71. DOI: 10.1038/nature21063. View

13.

Simbolo M, Mafficini A, Sikora K, Fassan M, Barbi S, Corbo V . Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol. 2016; 241(4):488-500. PMC: 5324596. DOI: 10.1002/path.4853. View

14.

Wang S, Parekh J, Zuraek M, Venook A, Bergsland E, Warren R . Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010; 145(3):276-80. DOI: 10.1001/archsurg.2010.10. View

15.

Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A . Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2016; 23(2):600-609. PMC: 6560642. DOI: 10.1158/1078-0432.CCR-16-1113. View

16.

Huber K, Narasimhan P, Shtukmaster S, Pfeifer D, Evans S, Sun Y . The LIM-Homeodomain transcription factor Islet-1 is required for the development of sympathetic neurons and adrenal chromaffin cells. Dev Biol. 2013; 380(2):286-98. PMC: 5544970. DOI: 10.1016/j.ydbio.2013.04.027. View

17.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

18.

Pape U, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R . ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016; 103(2):144-52. DOI: 10.1159/000443165. View

19.

Rosenbaum J, Guo Z, Baus R, Werner H, Rehrauer W, Lloyd R . INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. Am J Clin Pathol. 2015; 144(4):579-91. DOI: 10.1309/AJCPGZWXXBSNL4VD. View

20.

Sorbye H, Welin S, Langer S, Vestermark L, Holt N, Osterlund P . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2012; 24(1):152-60. DOI: 10.1093/annonc/mds276. View